⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 7, 2024Cardiovascular DiabetologyOpen Access

Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease

Viveca Ritsinger Kamila Avander Bo Lagerqvist Pia Lundman Anna Norhammar

View Full Paper

Ask AI

Bookmark

Share

Abstract

To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ritsinger et al. (2024) studied this question.

synapsesocial.com/papers/68e5d24cb6db643587568728 https://doi.org/10.1186/s12933-024-02365-1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA2024 · 48 citations
2Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVERcohort · 2022 · 86 citations
3Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitorscohort · 2025
4Temporal trends and clinical predictors of GLP-1 receptor agonist and SGLT2 inhibitor use after myocardial infarction among patients with type 2 diabetescohort · 2026
5Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists.2025 · 7 citations

SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review2025
Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study2021
Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study2022
BMI-discrepant phenotypes and transitions reveal sex-specific heterogeneity and reshape cardiometabolic risk in Chinese adultsCardiovascular Diabetology · 2026
Exercise intensity-dependent metabolic signatures and cardiovascular protection in type 2 diabetes: evidence from NMR metabolomics in the UK BiobankCardiovascular Diabetology · 2026

More from Cardiovascular Diabetology

More from Karolinska Institutet

More from Uppsala University

More from Saint Göran Hospital